Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Kaletra: Therapy With Double Protease Inhibitors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:
NCT01075191
First received: February 23, 2010
Last updated: January 14, 2013
Last verified: January 2013
History of Changes
Results First Received: September 28, 2012  
Study Type: Observational
Study Design: Observational Model: Cohort;   Time Perspective: Prospective
Condition: Human Immunodeficiency Virus

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
HIV-infected Participants

HIV-infected participants taking lopinavir/ritonavir (Kaletra) and one other protease inhibitor.

Lopinavir/ritonavir (Kaletra) dosing and administration according to the Summary of Product Characteristics (3 capsules twice daily or 2 tablets twice daily).

Participant Flow:   Overall Study
    HIV-infected Participants  
STARTED     60 [1]
Discontinued Year 1     7  
Discontinued Year 2     6  
Discontinued Year 3     5  
COMPLETED     42  
NOT COMPLETED     18  
Death                 1  
Intensification                 3  
Co-morbidities                 1  
Adverse Event                 4  
Noncompliance                 3  
Therapy Break                 3  
Patient's Wish                 2  
Unknown Reasons                 1  
[1] 65 participants were enrolled; 5 protocol violations were excluded from all analyses except safety.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
HIV-infected Participants

HIV-infected participants taking lopinavir/ritonavir (Kaletra) and one other protease inhibitor.

Lopinavir/ritonavir (Kaletra) dosing and administration according to the Summary of Product Characteristics (3 capsules twice daily or 2 tablets twice daily).

Baseline Measures
    HIV-infected Participants  
Number of Participants  
[units: participants]
 		  60  
Age [1]
[units: years]
Mean ± Standard Deviation 		  44.2  ± 9.0  
Gender  
[units: participants]
 		 
Female     7  
Male     53  
Region of Enrollment  
[units: participants]
 		 
Germany     60  
[1] In 10 participants, age was missing.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Participants With Human Immunodeficiency Virus -1 Ribonucleic Acid (HIV-1 RNA) <50 Copies/mL   [ Time Frame: Baseline (Week 0), Weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 ]
  Show Outcome Measure 1

2.  Secondary:   Change From Baseline in Absolute CD4 Cell Count   [ Time Frame: Baseline (Week 0), Weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 ]
  Show Outcome Measure 2

3.  Secondary:   Change From Baseline in Relative CD4 Cell Count   [ Time Frame: Baseline (Week 0), Weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 ]
  Show Outcome Measure 3

4.  Secondary:   Change From Baseline in Absolute CD8 Cell Count   [ Time Frame: Baseline (Week 0), Weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 ]
  Show Outcome Measure 4

5.  Secondary:   Change From Baseline in Relative CD8 Cell Count   [ Time Frame: Baseline (Week 0), Weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 ]
  Show Outcome Measure 5

6.  Secondary:   Change From Baseline in CD4/CD8 T-cell Ratio   [ Time Frame: Baseline (Week 0), Weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 ]
  Show Outcome Measure 6


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Global Medical Services
Organization: AbbVie (prior sponsor, Abbott)
phone: 800-633-9110


No publications provided


Responsible Party: AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier: NCT01075191     History of Changes
Other Study ID Numbers: P05-103
Study First Received: February 23, 2010
Results First Received: September 28, 2012
Last Updated: January 14, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices